SB 455-FN (2026): relative to coverage for GLP-1 medication under the state Medicaid plan.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA: “SB 455-FN (2026): relative to coverage for GLP-1 medication under the state Medicaid plan.” Granite Record, https://graniterecord.org/bill/2026/sb455. Accessed 19 Oct. 2026.
APA: Granite Record. (n.d.). SB 455-FN (2026): relative to coverage for GLP-1 medication under the state Medicaid plan. Retrieved 19 Oct. 2026, from https://graniterecord.org/bill/2026/sb455
Chicago: Granite Record. “SB 455-FN (2026): relative to coverage for GLP-1 medication under the state Medicaid plan.” Accessed 19 Oct. 2026. https://graniterecord.org/bill/2026/sb455.
BibTeX: @misc{bill-2026-sb455, title = {SB 455-FN (2026): relative to coverage for GLP-1 medication under the state Medicaid plan.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2026/sb455}, note = {Accessed 19 Oct. 2026} }

SB 455-FN (2026)

relative to coverage for GLP-1 medication under the state Medicaid plan.

Status: Killed
Term: 2025-2026
House committee: Commerce and Consumer Affairs
Senate committee: Health and Human Services
Subject: Insurance

The Story

It was introduced on January 7, 2026 and referred to the Senate Health and Human Services committee. The committee held a public hearing on February 11, 2026. The committee voted unanimously, 5–0, to recommend that the Senate pass it with changes (amendment 2026-0836s), and the report was placed on the consent calendar. The committee's amendment (2026-0836s) was adopted on a voice vote on March 5, 2026, changing the text of the bill. On March 5, 2026 the Senate voted to pass it with changes on a voice vote and ordered it to a third reading. It crossed to the House on March 12, 2026 and was referred to the House Commerce and Consumer Affairs committee. The committee held a public hearing on April 15, 2026, with 20 people signed in online: 19 in support and 1 as neutral. The committee held a work session on April 22, 2026. The committee met in executive session on April 29, 2026 to vote on its recommendation. The committee voted 13–2 to recommend that the House kill it, and the report was placed on the regular calendar. On May 14, 2026 the House voted to kill it on a voice vote.

Hearings and Sessions

February 11, 2026, 1:00 PM: hearing, Senate Health and Human Services, SH 100
March 5, 2026: consent calendar, Senate
April 15, 2026, 10:30 AM: public hearing, House Commerce and Consumer Affairs, GP 229
April 22, 2026, 10:00 AM: subcommittee work session, House Commerce and Consumer Affairs, GP 229
April 29, 2026, 10:00 AM: executive session, House Commerce and Consumer Affairs, GP 229
May 14, 2026: floor debate, House

Votes

March 5, 2026, Senate: Ought to Pass with Amendment #2026-0836s — voice vote, passed
May 14, 2026, House: Inexpedient to Legislate — voice vote, passed

The Docket

January 7, 2026: Introduced 01/07/2026 and Referred to Health and Human Services
February 11, 2026: Hearing: 02/11/2026, Room 100, SH, 01:00 pm
March 5, 2026: Committee Report: Ought to Pass with Amendment # 2026-0836s, 03/05/2026; Vote 5-0; CC
March 5, 2026: Ought to Pass with Amendment #2026-0836s, MA, VV; OT3rdg; 03/05/2026
March 5, 2026: Committee Amendment # 2026-0836s, AA, VV; 03/05/2026
March 12, 2026: Introduced (in recess of) 03/12/2026 and referred to Commerce and Consumer Affairs
April 15, 2026: Public Hearing: 04/15/2026 10:30 am GP 229
April 22, 2026: Subcommittee Work Session: 04/22/2026 10:00 am GP 229
April 29, 2026: Executive Session: 04/29/2026 10:00 am GP 229
April 29, 2026: Committee Report: Inexpedient to Legislate 04/29/2026 (Vote 13-2; RC)
May 14, 2026: Inexpedient to Legislate: MA VV 05/14/2026

Laws It Would Change

RSA 167